Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor Combined With Azacitidine and Venetoclax in Newly Diagnosed High-risk Myeloid Tumors With TP53 Mutations
NCT07632170Not yet recruiting
- Start
- Nov 2026
- Primary completion
- Oct 2027
- Countries
- 1
01
Overview
Open-label, single-arm trial of selinexor in Extramedullary leukemia (EML). Primary endpoints: Overall Response Rate at 6 months and Complete Response Rate at 6 months. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
selinexor
03
Conditions
Extramedullary leukemia (EML)
Beyond the preview
Go deeper on NCT07632170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07632170.